Boston Scientific Corporation $BSX Stock: Avidian Wealth Enterprises LLC Increases Stake

Key Points

• Avidian Wealth Enterprises increased its Boston Scientific stake by 372.9% in the third quarter to 31,451 shares valued at approximately $1.37 million. Institutional investors collectively own 89.07% of the company.
• Boston Scientific reported quarterly revenue of $5.44 billion and EPS of $0.86, exceeding analyst expectations, while revenue grew 7.5% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $66.31.
• The stock has faced significant weakness, trading near a new 52-week low around $41.50 and below its 50- and 200-day moving averages. Recent developments include a patent lawsuit against Johnson & Johnson, a management reorganization, and Barclays initiating coverage with an Equal Weight rating.

Avidian Wealth Enterprises LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 372.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,451 shares of the medical equipment provider's stock after purchasing an additional 24,801 shares during the period. Avidian Wealth Enterprises LLC's holdings in Boston Scientific were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Boston Scientific during the second quarter worth approximately $5,534,781,000. State Street Corp lifted its position in Boston Scientific by 1.4% in the fourth quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider's stock valued at $6,278,422,000 after purchasing an additional 920,495 shares during the last quarter. Primecap Management Co. CA purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $2,156,233,000. Jupiter Topco LLC purchased a new stake in shares of Boston Scientific during the second quarter valued at approximately $803,357,000. Finally, Janus Henderson Group PLC grew its holdings in shares of Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider's stock worth $1,035,202,000 after purchasing an additional 3,907,981 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Trading Up 1.6%

Shares of NYSE BSX opened at $42.71 on Friday. The stock has a market capitalization of $61.90 billion, a P/E ratio of 17.29, a PEG ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The business's 50 day moving average is $46.56 and its two-hundred day moving average is $50.65. Boston Scientific Corporation has a 1-year low of $41.38 and a 1-year high of $105.65.

Boston Scientific (NYSE:BSX - Get Free Report) last released its earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the business earned $0.75 EPS. The business's revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 3.25 EPS for the current year.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific sued Johnson & Johnson over alleged patent infringement involving a tool used in heart procedures. Although the litigation creates uncertainty, a successful outcome could help protect Boston Scientific’s intellectual property and competitive position. Boston Scientific sues J&J for patent infringement over heart procedure tool
• Neutral Sentiment: The company appointed Joseph Fitzgerald as chief operating officer and is reorganizing into three operating segments. The changes could improve accountability and execution, but investors may initially view the restructuring as an indication that management is seeking to streamline operations. Boston Scientific Names Joseph Fitzgerald as COO Why Is Boston Scientific Reorganizing Into Three Segments Under A New COO?
• Neutral Sentiment: Barclays initiated coverage with an Equal Weight rating, also described in related coverage as a Hold. The stance suggests the firm sees limited near-term outperformance potential rather than a strong bullish or bearish catalyst. Barclays initiates coverage of Boston Scientific with equal-weight
• Negative Sentiment: BSX reached a new 52-week low near $41.50 amid elevated trading volume. The stock remains substantially below its 50-day average of $46.64 and 200-day average of $50.71, signaling weak momentum and continued investor caution. Boston Scientific Reaches New 1-Year Low

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on BSX shares. Argus reiterated a "hold" rating on shares of Boston Scientific in a report on Friday, July 31st. Evercore set a $65.00 price objective on shares of Boston Scientific in a report on Monday, July 6th. Needham & Company LLC dropped their target price on shares of Boston Scientific from $77.00 to $57.00 and set a "buy" rating for the company in a research report on Wednesday, July 8th. Oppenheimer cut their price objective on Boston Scientific from $85.00 to $65.00 and set an "outperform" rating on the stock in a research report on Monday, September 21st. Finally, Royal Bank Of Canada dropped their price target on Boston Scientific from $85.00 to $70.00 and set an "outperform" rating on the stock in a research report on Thursday, July 30th. Twenty-two equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific has an average rating of "Moderate Buy" and a consensus price target of $66.31.

Insider Buying and Selling

In other Boston Scientific news, Director David Habiger bought 2,100 shares of the company's stock in a transaction on Wednesday, August 5th. The shares were bought at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the acquisition, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Edward Ludwig purchased 5,000 shares of the firm's stock in a transaction on Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company's stock, valued at approximately $1,380,727.32. The trade was a 19.72% increase in their position. The SEC filing for this purchase provides additional information. Insiders acquired a total of 194,522 shares of company stock valued at $9,385,210 over the last three months. 0.34% of the stock is owned by company insiders.

About Boston Scientific

Boston Scientific Corporation is a global medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of medical conditions. Its products are designed to support minimally invasive procedures across areas including cardiovascular care, endoscopy, urology, pelvic health and neuromodulation.

The company's portfolio includes devices for interventional cardiology and peripheral interventions, electrophysiology and cardiac rhythm management, gastrointestinal and pulmonary procedures, kidney stone and prostate treatments, urinary and pelvic health, and chronic pain management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.